Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Jul 1;13(13):2245.
doi: 10.3390/diagnostics13132245.

SARS-CoV-2 Testing of Emergency Department Patients Using cobas® Liat® and eazyplex® Rapid Molecular Assays

Renate Egerer  1 , Birgit Edel  1 , Franziska Hornung  1 , Stefanie Deinhardt-Emmer  1 , Michael Baier  1 , Jan-Christoph Lewejohann  2 , Wolfgang Pfister  3 , Bettina Löffler  1 , Jürgen Rödel  1
Affiliations

SARS-CoV-2 Testing of Emergency Department Patients Using cobas® Liat® and eazyplex® Rapid Molecular Assays

Renate Egerer et al. Diagnostics (Basel). .

Abstract

Rapid testing for Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) of patients presenting to emergency departments (EDs) facilitates the decision for isolation on admission to hospital wards. Differences in the sensitivity of molecular assays have implications for diagnostic workflows. This study evaluated the performance of the cobas® Liat® RT-PCR, which is routinely used as the initial test for ED patients in our hospitals, compared with the eazyplex® RT-LAMP. A total of 378 oropharyngeal and nasal swabs with positive Liat® results were analysed. Residual sample aliquots were tested using NeuMoDx™, cobas® RT-PCR, and the eazyplex® assay. Patients were divided into asymptomatic (n = 157) and symptomatic (n = 221) groups according to the WHO case definition. Overall, 14% of positive Liat® results were not confirmed by RT-PCR. These samples were mainly attributed to 26.8% of asymptomatic patients, compared to 3.8% of the symptomatic group. Therefore, positive Liat® results were used to provisionally isolate patients in the ED until RT-PCR results were available. The eazyplex® assay identified 62% and 90.6% of RT-PCR-confirmed cases in asymptomatic and symptomatic patients, respectively. False-negative eazyplex® results were associated with RT-PCR Ct values > 30, and were more frequent in the asymptomatic group than in the symptomatic group (38.1% vs. 5.1%, respectively). Both the Liat® and eazyplex® assays are suitable for testing symptomatic patients. Their use in screening asymptomatic patients depends on the need to exclude any infection or identify those at high risk of transmission.

Keywords: POC; SARS-CoV-2; emergency department; rapid diagnostic test.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Proposed workflow combining the (a) cobas® Liat® and (b) eazyplex® SARS-CoV-2 assays for rapid diagnosis of SARS-CoV-2 infection.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Kepka S., Ohana M., Séverac F., Muller J., Bayle E., Ruch Y., Laugel E., Oberlin M., Soli M., Hansmann Y., et al. Rapid antigen test combined with chest computed tomography to rule out COVID-19 in patients admitted to the emergency department. J. Clin. Med. 2021;10:3455. doi: 10.3390/jcm10163455. - DOI - PMC - PubMed
    1. Möckel M., Corman V.M., Stegemann M.S., Hofmann J., Stein A., Jones T.C., Gastmeier P., Seybold J., Offermann R., Bachmann U., et al. SARS-CoV-2 antigen rapid immunoassay for diagnosis of COVID-19 in the emergency department. Biomarkers. 2021;26:213–220. doi: 10.1080/1354750X.2021.1876769. - DOI - PMC - PubMed
    1. Bruno A., de Mora D., Freire-Paspuel B., Rodriguez A.S., Paredes-Espinosa M.B., Olmedo M., Sanchez M., Romero J., Paez M., Gonzalez M., et al. Analytical and clinical evaluation of a heat shock SARS-CoV-2 detection method without RNA extraction for N and E genes RT-qPCR. Int. J. Infect. Dis. 2021;109:315–320. doi: 10.1016/j.ijid.2021.06.038. - DOI - PMC - PubMed
    1. Hansen G., Marino J., Wang Z.X., Beavis K.G., Rodrigo J., Labog K., Westblade L.F., Jin R., Love N., Ding K., et al. Clinical performance of the point-of-care cobas Liat for detection of SARS-CoV-2 in 20 minutes: A multicenter study. J. Clin. Microbiol. 2021;59:e02811-20. doi: 10.1128/JCM.02811-20. - DOI - PMC - PubMed
    1. NguyenVan J.C., Gerlier C., Pilmis B., Mizrahi A., Péan de Ponfilly G., Khaterchi A., Enouf V., Ganansia O., Le Monnier A. Prospective evaluation of ID NOW COVID-19 assay used as point-of-care test in an emergency department. J. Clin. Virol. 2021;145:105021. doi: 10.1016/j.jcv.2021.105021. - DOI - PMC - PubMed

LinkOut - more resources